

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Bod Science Limited (Subject to a Deed of Company Arrangement)

ABN

89 601 225 441

Quarter ended ("current quarter")

30 June 2025

Consolidated statement of cash flows	Current quarter	Year to date (12 months)
	\$A'000	\$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers ¹	388	1,222
1.2 Payments for		
(a) research and development ²	(13)	(20)
(b) product manufacturing and operating costs ¹	(124)	(361)
(c) advertising and marketing	(7)	(25)
(d) leased assets	-	-
(e) staff costs	(236)	(964)
(f) administration and corporate costs ²	(147)	(548)
1.3 Dividends received	-	-
1.4 Interest received	7	20
1.5 Interest and other costs of finance paid	-	(1)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives ³	678	678
1.8 Other ⁴	312	946
1.9 Net cash from / (used in) operating activities	858	947
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-

Consolidated statement of cash flows		Current quarter	Year to date (12 months)
		\$A'000	\$A'000
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property ²	-	125
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received	-	-
2.5	Other	-	-
2.6	Net cash from / (used in) investing activities	-	125

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	(9)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	-	(9)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	179	(26)
4.2	Net cash from / (used in) operating activities (item 1.9 above)	858	947
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	125

Consolidated statement of cash flows		Current quarter	Year to date (12 months)
		\$A'000	\$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	(9)
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	1,037	1,037

5.	Reconciliation of cash and cash equivalents	Current quarter	Previous quarter
	at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	\$A'000	\$A'000
5.1	Bank balances	1,498	640
5.2	Call deposits	-	-
5.3	Bank overdrafts	(461)	(461)
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,037	179

6.	Payments to related parties of the entity and their associates	Current quarter
		\$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1: <ul style="list-style-type: none"> • Salaries/fees paid to directors 	35
6.2	Aggregate amount of payments to related parties and their associates included in item 1	35

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7. Financing facilities	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i>		
<i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	858
8.2 Cash and cash equivalents at quarter end (item 4.6)	1,037
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	1,037
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Not applicable	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Not applicable	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Not applicable	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 22 July 2025

Authorised by: **Deed Administrator of Bod Science Limited (Subject to a Deed of Company Arrangement)**

Notes

1. The June 2025 quarter receipts from customers and payments for product manufacturing and operating costs have both been increased by \$89k, representing the grossing up of these line items for payments made by Bod distributors directly to a Bod supplier in relation to the supply of products to Bod by that supplier which were subsequently sold to that distributor.
2. During Q2, Bod received an amount of \$176k in relation to the sale of certain items of its intellectual property rights. The amount received was allocated as follows: \$125k for the sale of intellectual property (reported in proceeds from disposal of intellectual property); \$13k for the reimbursement of research and development costs previously incurred (reported in payments for research and development); and \$38k for the reimbursement of legal fees and patent fees in relation to the intellectual property rights (reported in payments for administration and corporate costs).
3. During the June 2025 quarter, Bod received an R&D tax incentive relating to R&D spend incurred during the year ended 30 June 2024. The amount of the R&D incentive recognised was \$678k and the amount received in cash was \$627k, after offsetting amounts owed to the ATO of \$51k. An amount of \$400k of this R&D tax incentive is held in trust for the benefit of Biortica if the acquisition of Bod completes.
4. During the June 2025 quarter, and in accordance with the conditions of the Heads of Agreement between Bod and Biortica Agrimed Limited (Biortica) signed on 9 February 2024, Biortica has partially funded the ongoing trading costs of the company. The funding from Biortica has been disclosed as other inflows from operating activities, while the costs have been disclosed as outflows on the relevant lines within operating activities.